Professor Nagy Habib is Lead Clinician for the HPB Unit at Imperial College Healthcare NHS Trust and Head of the Department of HPB Surgery at Imperial College London. In June 2007 he was also appointed Pro Rector for Commercial Affairs at the university.
Professor Habib is a translational researcher who pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was also the first to publish from the West a clinical trial on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency.
As a translational researcher he has followed and published on the evolution of molecular biology of tumours from oncogene, tumour suppressor gene, epigenetic modification, gene therapy, stem cell therapy, saRNA and RNA aptamers.
He was the inventor and was co-author on the first publication to describe the use for radiofrequency in devices used in liver surgery (Habib 4X), as well as interventional endoscopy (Habib EndoHPB) and interventional radiology (Habib VesOpen).
He holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. In November 2012 he was awarded TAKREEM LAUREATE for his contribution to technology and science.
Presented at Events Covering:
Areas of Interest:
SaRNA, Stem cells for therapeutic intent, Liver and pancreatic cancer, Innovation in medical devices
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology, drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.